Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma

Background: Renal cell carcinoma is the third most prevalent urological cancer worldwide and about 30% of patients present with metastatic disease at the time of diagnosis. Systemic treatments for metastatic renal cell carcinoma have improved recently. Vascular endothelial growth factor targeting th...

Descripción completa

Detalles Bibliográficos
Autores principales: Billon, Emilien, Walz, Jochen, Brunelle, Serge, Thomassin, Jeanne, Salem, Naji, Guerin, Mathilde, Vicier, Cecile, Dermeche, Slimane, Albiges, Laurence, Tantot, Florence, Nenan, Soazig, Pignot, Geraldine, Gravis, Gwenaëlle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795279/
https://www.ncbi.nlm.nih.gov/pubmed/31649889
http://dx.doi.org/10.3389/fonc.2019.01033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795279/
https://www.ncbi.nlm.nih.gov/pubmed/31649889
http://dx.doi.org/10.3389/fonc.2019.01033

Ejemplares similares